Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CYD-TDV
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
CYD-TDV, also known by its brand name Dengvaxia, is a live, attenuated tetravalent vaccine developed by Sanofi Pasteur. It is designed to prevent dengue fever by inducing an immune response against all four serotypes of the dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4). The vaccine is administered via subcutaneous injection.
- Brand names
- Dengvaxia
- Other names
- CYD dengue vaccinechimeric yellow fever-dengue tetravalent dengue vaccine
02
Targets
E (Tick-borne encephalitis virus envelope protein)
Beyond the preview
Go deeper on CYD-TDV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CYD-TDV.